181 related articles for article (PubMed ID: 27344679)
1. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
Usui N
Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
[No Abstract] [Full Text] [Related]
2. Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.
Knepper TC; Saller J; Walko CM
Oncology (Williston Park); 2017 Feb; 31(2):138-46. PubMed ID: 28205194
[TBL] [Abstract][Full Text] [Related]
3. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
Usui N
Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
[No Abstract] [Full Text] [Related]
4. [Hematologic Malignancies/Pediatric Malignancies New Therapeutic Strategy for Hematologic Malignancies].
Usui N
Gan To Kagaku Ryoho; 2018 May; 45(5):793-794. PubMed ID: 30026439
[No Abstract] [Full Text] [Related]
5. [Current issues concerning drug development for pediatric hematologic malignancies].
Sekimizu M
Rinsho Ketsueki; 2016 Jun; 57(6):693-700. PubMed ID: 27384847
[TBL] [Abstract][Full Text] [Related]
6. [Hematologic malignancies/pediatric malignancies].
Usui N
Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
[No Abstract] [Full Text] [Related]
7. New drugs and pharmacological interactions in real life.
Stathis A
Hematol Oncol; 2021 Jun; 39 Suppl 1():78-82. PubMed ID: 34105810
[TBL] [Abstract][Full Text] [Related]
8. Balancing patient value and payer cost in hematologic malignancies: can it be done?
Allen PB; Flowers CR
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):123-126. PubMed ID: 29486601
[No Abstract] [Full Text] [Related]
9. Idelalisib approved for trio of blood cancers.
Cancer Discov; 2014 Oct; 4(10):OF6. PubMed ID: 25274697
[No Abstract] [Full Text] [Related]
10. [A role of new molecular-target drugs for hematologic malignancies].
Usui N
Gan To Kagaku Ryoho; 2015 May; 42(5):548-9. PubMed ID: 26054087
[No Abstract] [Full Text] [Related]
11. New targets for hematologic malignancies.
Bradner J
Clin Adv Hematol Oncol; 2013 Jun; 11(6):375-6. PubMed ID: 24472807
[No Abstract] [Full Text] [Related]
12. Mechanisms of drug resistance in hematologic malignancies.
Dalton WS
Semin Hematol; 1997 Oct; 34(4 Suppl 5):3-8. PubMed ID: 9408955
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine: a new therapeutic option for hematologic malignancies.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
[No Abstract] [Full Text] [Related]
14. Arsenic derivatives as therapeutic agents for hematologic malignancies.
Verstovsek S; Estrov Z
Leuk Res; 2004 Sep; 28(9):901-3. PubMed ID: 15234564
[No Abstract] [Full Text] [Related]
15. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
16. New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction.
Kantarjian H
Semin Hematol; 1998 Jul; 35(3 Suppl 4):1-2. PubMed ID: 9779875
[No Abstract] [Full Text] [Related]
17. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
18. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.
Whittington MD; McQueen RB; Campbell JD
JAMA Pediatr; 2018 May; 172(5):409-410. PubMed ID: 29554182
[No Abstract] [Full Text] [Related]
19. Antibodies and hematologic malignancies.
Smith MR
Cancer J; 2008; 14(3):184-90. PubMed ID: 18536558
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.
Zhan F; Zangari M; Qiu L
Biomed Res Int; 2015; 2015():384575. PubMed ID: 26000289
[No Abstract] [Full Text] [Related]
[Next] [New Search]
